Report cover image

Non-Muscle Invasive Bladder Cancer (NMIBC) Market

Publisher BlueWeave Consulting
Published Jul 15, 2025
Length 544 Pages
SKU # BLWC20706769

Description

Non-Muscle Invasive Bladder Cancer (NMIBC) Market, By Stage (Low-risk NMIBC, Intermediate-risk NMIBC, High-risk NMIBC); By Treatment Type (Surgery (TURBT), Intravesical Therapy, Immunotherapy, Targeted Therapy); By End User (Hospital Pharmacies, Cancer Specialty Centers, Retail & Online Pharmacies); By Region (North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA)), Global Trend Analysis, Competitive Landscape & Forecast, 2019–2031Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market Size to Touch USD 5.9 Billion by 2031

Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market is flourishing primarily due to growing awareness about the disease, along with government-driven healthcare initiatives.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market size by value at USD 3.86 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market size to expand at a significant CAGR of 6.25% reaching a value of USD 5.89 billion by 2031. Growing awareness about bladder cancer symptoms and the critical role of early detection, coupled with the implementation of screening programs, is facilitating earlier diagnoses and improving patient outcomes. It is predicted to have a favorable influence on the growth of Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market over the forecast period.

Opportunity – Rising Adoption of Targeted Therapies and Immunotherapies

The growing trend of using targeted therapies and immunotherapies is forecast to boost the growth of Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market. Patients and doctors want treatments that work better and are tailored to each person’s needs. Targeted therapies are designed to attack specific cancer cells without harming healthy ones, while immunotherapies help the body’s own immune system fight the cancer. This shift driven by the innovative treatment methods can be more effective and often have fewer side effects than traditional methods, giving patients a better chance at recovery and a higher quality of life.

High Risk Type Segment Dominates Global NMIBC Market

The high-risk segment dominates Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market by stage. This is because most new treatments, clinical trials, and research efforts are focused on high-risk patients, who have the greatest chance of their cancer coming back or getting worse. As a result, high-risk NMIBC accounts for the largest share of the market, while low-risk and intermediate-risk cases make up much smaller portions. This focus on high-risk NMIBC is driven by the urgent need for more effective therapies and better outcomes for these patients.

North America Leads Global NMIBC Market

North America holds a major market share in Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market, as it has the highest number of bladder cancer cases, advanced healthcare systems, and better access to new treatments and technologies. Hospitals and clinics in North America are well-equipped for early diagnosis and offer the latest therapies, which helps patients get better care. While Europe is the second largest market due to its aging population and access to modern treatments, Asia Pacific is growing the fastest thanks to rising cancer rates and more investment in healthcare, but North America remains the top region in terms of overall market size and leadership

Impact of Escalating Geopolitical Tensions on Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market

Escalating geopolitical tensions are having a profound impact on the growth of Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market by disrupting pharmaceutical supply chains, increasing costs, and fragmenting regulatory landscapes. Trade disputes, such as the sharp rise in US tariffs on Chinese pharmaceutical imports and active pharmaceutical ingredients (APIs), have significantly raised production costs and forced companies to reassess their global sourcing strategies. Heightened protectionism and new legislation, like the U.S. BIOSECURE Act, are compelling pharmaceutical firms to sever partnerships with China-based manufacturers and establish separate, often more expensive, supply chains to maintain market access and government contracts.

Competitive Landscape

Major players operating in Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market include TARIS Biomedical LLC, Merck & Co., Inc., Herantis Pharma Oyj, Viventia Bio Inc., Telormedix SA, Ferring B.V., Altor BioScience Corporation, Novartis AG, Pfizer Inc., GSK plc, Sanofi S.A., Eli Lilly and Company, AstraZeneca, UroGen Pharma, Johnson & Johnson, CG Oncology, ImmunityBio, Theralase Technologies, Protara Therapeutics, enGene, Celgene Corporation, and Hoffmann-La Roche Ltd. These leading companies are actively involved in the research, development, and commercialization of therapies for Non-Muscle Invasive Bladder Cancer (NMIBC). To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The report's in-depth analysis provides information about growth potential, upcoming trends, and Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

544 Pages
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights
3.1. DROC Analysis
3.1.1. Growth Drivers
3.1.1.1. Rising Prevalence of Bladder Cancer
3.1.1.2. Advancements in Treatment Options
3.1.1.3. Growing Awareness and Early Detection
3.1.2. Restraints
3.1.2.1. High Cost of Therapy
3.1.2.2. Treatment Resistance and High Recurrence Rates
3.1.3. Opportunities
3.1.3.1. Advancements in Targeted and Personalized Medicine
3.1.3.2. Increasing Healthcare Spending and Government Investment
3.1.4. Challenges
3.1.4.1. Limited Access and Insurance Barriers
3.1.4.2. Treatment Side Effects and Quality of Life Impact
3.2. Porter’s Five Forces Analysis
3.2.1. Bargaining Power of Suppliers
3.2.2. Bargaining Power of Buyers
3.2.3. Threat of New Entrants
3.2.4. Threat of Substitutes
3.2.5. Intensity of Rivalry
4. Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market: Value Chain Analysis
5. Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market: Regulatory Framework
6. Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market: Marketing Strategies
7. Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market: Pricing Analysis
8. Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market: Geography Analysis
8.1. Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market, Geographical Analysis, 2024
8.2. Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market Attractiveness Analysis, 2024–2031
9. Global Non-Muscle Invasive Bladder Cancer (NMIBC) Market Overview
9.1. Market Size & Forecast, 2019–2031
9.1.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
9.2.1.By Stage
9.2.1.1. Low-risk NMIBC
9.2.1.2. Intermediate-risk NMIBC
9.2.1.3. High-risk NMIBC
9.2.2. By Treatment Type
9.2.2.1. Surgery (TURBT)
9.2.2.2. Intravesical Therapy
9.2.2.3. Immunotherapy
9.2.2.4. Targeted Therapy
9.2.3. By End User
9.2.3.1. Hospital Pharmacies
9.2.3.2. Cancer Specialty Centers
9.2.3.3. Retail & Online Pharmacies
9.2.4. By Region
9.2.4.1.1. North America
9.2.4.1.2. Europe
9.2.4.1.3. Asia Pacific (APAC)
9.2.4.1.4. Latin America (LATAM)
9.2.4.1.5. Middle East and Africa (MEA)
10. North America Non-Muscle Invasive Bladder Cancer (NMIBC) Market
10.1. Market Size & Forecast, 2019–2031
10.1.1. By Value (USD Billion)
10.2. Market Share & Forecast
10.2.1. By Stage
10.2.2. By Treatment Type
10.2.3. By End User
10.2.4. By Country
10.2.4.1. United States
10.2.4.1.1. By Stage
10.2.4.1.2. By Treatment Type
10.2.4.1.3. By End User
10.2.4.2. Canada
10.2.4.2.1. By Stage
10.2.4.2.2. By Treatment Type
10.2.4.2.3. By End User
11. Europe Non-Muscle Invasive Bladder Cancer (NMIBC) Market
11.1. Market Size & Forecast, 2019–2031
11.1.1. By Value (USD Billion)
11.2. Market Share & Forecast
11.2.1.1. By Stage
11.2.1.2. By Treatment Type
11.2.1.3. By End User
11.2.1.4. By Country
11.2.1.5. Germany Non-Muscle Invasive Bladder Cancer (NMIBC) Market
11.2.1.5.1. By Stage
11.2.1.5.2. By Treatment Type
11.2.1.5.3. By End User
11.2.1.6. United Kingdom Non-Muscle Invasive Bladder Cancer (NMIBC) Market
11.2.1.6.1. By Stage
11.2.1.6.2. By Treatment Type
11.2.1.6.3. By End User
11.2.1.7. Italy Non-Muscle Invasive Bladder Cancer (NMIBC) Market
11.2.1.7.1. By Stage
11.2.1.7.2. By Treatment Type
11.2.1.7.3. By End User
11.2.1.8. France Non-Muscle Invasive Bladder Cancer (NMIBC) Market
11.2.1.8.1. By Stage
11.2.1.8.2. By Treatment Type
11.2.1.8.3. By End User
11.2.1.9. Spain Non-Muscle Invasive Bladder Cancer (NMIBC) Market
11.2.1.9.1. By Stage
11.2.1.9.2. By Treatment Type
11.2.1.9.3. By End User
11.2.1.10. Belgium Non-Muscle Invasive Bladder Cancer (NMIBC) Market
11.2.1.10.1. By Stage
11.2.1.10.2. By Treatment Type
11.2.1.10.3. By End User
11.2.1.11. Russia
11.2.1.11.1. By Stage
11.2.1.11.2. By Treatment Type
11.2.1.11.3. By End User
11.2.1.12. The Netherlands Non-Muscle Invasive Bladder Cancer (NMIBC) Market
11.2.1.12.1. By Stage
11.2.1.12.2. By Treatment Type
11.2.1.12.3. By End User
11.2.1.12.4.
11.2.1.13. Rest of Europe
11.2.1.13.1. By Stage
11.2.1.13.2. By Treatment Type
11.2.1.13.3. By End User
12. Asia Pacific Non-Muscle Invasive Bladder Cancer (NMIBC) Market
12.1. Market Size & Forecast, 2019–2031
12.2.By Value (USD Billion)
12.3.Market Share & Forecast
12.3.1. By Stage
12.3.2. By Treatment Type
12.3.3. By End User
12.3.3.1. China Non-Muscle Invasive Bladder Cancer (NMIBC) Market
12.3.3.1.1. By Stage
12.3.3.1.2. By Treatment Type
12.3.3.1.3. By End User
12.3.3.2. India Non-Muscle Invasive Bladder Cancer (NMIBC) Market
12.3.3.2.1. By Stage
12.3.3.2.2. By Treatment Type
12.3.3.2.3. By End User
12.3.3.3. Japan Non-Muscle Invasive Bladder Cancer (NMIBC) Market
12.3.3.3.1. By Stage
12.3.3.3.2. By Treatment Type
12.3.3.3.3. By End User
12.3.3.4. South Korea Non-Muscle Invasive Bladder Cancer (NMIBC) Market
12.3.3.4.1. By Stage
12.3.3.4.2. By Treatment Type
12.3.3.4.3. By End User
12.3.3.5. Australia and New Zealand Non-Muscle Invasive Bladder Cancer (NMIBC) Market
12.3.3.5.1. By Stage
12.3.3.5.2. By Treatment Type
12.3.3.5.3. By End User
12.3.3.6. Indonesia Non-Muscle Invasive Bladder Cancer (NMIBC) Market
12.3.3.6.1. By Stage
12.3.3.6.2. By Treatment Type
12.3.3.6.3. By End User
12.3.3.7. Malaysia Non-Muscle Invasive Bladder Cancer (NMIBC) Market
12.3.3.7.1. By Stage
12.3.3.7.2. By Treatment Type
12.3.3.7.3. By End User
12.3.3.8. Singapore
12.3.3.8.1. By Stage
12.3.3.8.2. By Treatment Type
12.3.3.8.3. By End User
12.3.3.9. Vietnam
12.3.3.9.1. By Stage
12.3.3.9.2. By Treatment Type
12.3.3.9.3. By End User
12.3.3.10. Rest of APAC
12.3.3.10.1. By Stage
12.3.3.10.2. By Treatment Type
12.3.3.10.3. By End User
13. Latin America Non-Muscle Invasive Bladder Cancer (NMIBC) Market
13.1. Market Size & Forecast, 2019–2031
13.1.1. By Value (USD Billion)
13.2. Market Share & Forecast
13.2.1. By Stage
13.2.2. By Treatment Type
13.2.3. By End User
13.2.4. By Country
13.2.4.1. Brazil
13.2.4.1.1. By Stage
13.2.4.1.2. By Treatment Type
13.2.4.1.3. By End User
13.2.4.2. Mexico
13.2.4.2.1. By Stage
13.2.4.2.2. By Treatment Type
13.2.4.2.3. By End User
13.2.4.3. Argentina
13.2.4.3.1. By Stage
13.2.4.3.2. By Treatment Type
13.2.4.3.3. By End User
13.2.4.4. Peru
13.2.4.4.1. By Stage
13.2.4.4.2. By Treatment Type
13.2.4.4.3. By End User
13.2.4.5. Rest of LATAM
13.2.4.5.1. By Stage
13.2.4.5.2. By Treatment Type
13.2.4.5.3. By End User
14. Middle East and Africa Non-Muscle Invasive Bladder Cancer (NMIBC) Market
14.1. Market Size & Forecast, 2019–2031
14.1.1. By Value (USD Billion)
14.2. Market Share & Forecast
14.2.1. By Stage
14.2.2. By Treatment Type
14.2.3. By End User
14.2.4. By Country
14.2.4.1. Saudi Arabia
14.2.4.1.1. By Stage
14.2.4.1.2. By Treatment Type
14.2.4.1.3. By End User
14.2.4.2. UAE
14.2.4.2.1. By Stage
14.2.4.2.2. By Treatment Type
14.2.4.2.3. By End User
14.2.4.3. Qatar
14.2.4.3.1. By Stage
14.2.4.3.2. By Treatment Type
14.2.4.3.3. By End User
14.2.4.4. Kuwait
14.2.4.4.1. By Stage
14.2.4.4.2. By Treatment Type
14.2.4.4.3. By End User
14.2.4.5. South Africa
14.2.4.5.1. By Stage
14.2.4.5.2. By Treatment Type
14.2.4.5.3. By End User
14.2.4.6. Nigeria
14.2.4.6.1. By Stage
14.2.4.6.2. By Treatment Type
14.2.4.6.3. By End User
14.2.4.7. Algeria
14.2.4.7.1. By Stage
14.2.4.7.2. By Treatment Type
14.2.4.7.3. By End User
14.2.4.8. Rest of MEA
14.2.4.8.1. By Stage
14.2.4.8.2. By Treatment Type
14.2.4.8.3. By End User
15. Competitive Landscape
15.1. List of Key Players and Their Offering
15.2. Company Share Analysis, 2024
15.3. Competitive Benchmarking, By Operating Parameters
15.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)
16. Impact of Escalating Geopolitical Tensions on Non-Muscle Invasive Bladder Cancer (NMIBC) Market
17. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
17.1. TARIS Biomedical LLC
17.2. Merck & Co., Inc.
17.3. Herantis Pharma Oyj
17.4. Viventia Bio Inc.
17.5. Telormedix SA
17.6. Ferring B.V.
17.7. Altor BioScience Corporation
17.8. Novartis AG
17.9. Pfizer Inc.
17.10. GSK plc
17.11. Sanofi S.A.
17.12. Eli Lilly and Company
17.13. AstraZeneca
17.14. UroGen Pharma
17.15. Johnson & Johnson
17.16. CG Oncology
17.17. ImmunityBio
17.18. Theralase Technologies
17.19. Protara Therapeutics
17.20. enGene
17.21. Celgene Corporation
17.22. Hoffmann-La Roche Ltd
17.23. Other Prominent Players
18. Key Strategic Recommendations
19. Research Methodology
19.1.Qualitative Research
19.1.1.Primary & Secondary Research
19.2.Quantitative Research
19.3.Market Breakdown & Data Triangulation
19.3.1.Secondary Research
19.3.2.Primary Research
19.4.Breakdown of Primary Research Respondents, By Region
19.5.Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us